Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.
Company codeHBIO
Company nameHarvard Bioscience Inc
IPO dateOct 21, 2013
Founded at2000
CEOMr. James W. (Jim) Green
Number of employees330
Security typeOrdinary Share
Fiscal year-endOct 21
Address84 October Hill Rd
CityHOLLISTON
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code01746-1371
Phone15088938999
Websitehttps://www.harvardbioscience.com/
Company codeHBIO
IPO dateOct 21, 2013
Founded at2000
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data